{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.2","upperLimit":"46.6","value":"31.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.\n\nComplete remission was defined as meeting all 3 of the following criteria:\n\n* less than or equal to 5% blasts in the bone marrow;\n* no evidence of disease;\n* full recovery of peripheral blood counts: platelets \\> 100,000/μl, and absolute neutrophil count (ANC) \\> 1000/μl.\n\nParticipants without a post-baseline disease assessment were considered non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"All participants who received an infusion of blinatumomab","reportingStatus":"POSTED","timeFrame":"Approximately 12 weeks, as of the data cut-off date of 20 May 2015","title":"Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles","type":"SECONDARY","unitOfMeasure":"percentage of participants"}